Adial Pharmaceuticals (ADIL) Price & Analysis

Compare

604 Followers

ADIL Stock Chart & Stats

$0.22

-$0.03(-2.80%)

At close: Jan 08 4:00 PM EST

$0.22

-$0.03(-2.80%)

Day’s Range― - ―

52-Week Range$0.21 - $1.30

Previous CloseN/A

Volume36.45K

Average Volume (3M)746.19K

Market Cap

$5.92M

Enterprise Value$503.81K

Total Cash (Recent Filing)$4.61M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.05

Next Earnings

Mar 26, 2026

EPS Estimate

-0.08

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.08

Shares Outstanding27,779,263

10 Day Avg. Volume779,793

30 Day Avg. Volume746,186

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)4.62

Price to Sales (P/S)0.00

P/FCF Ratio-2.71

Enterprise Value/Market Cap0.09

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-1.79K

Enterprise Value/Ebitda-0.06

Forecast

1Y Price Target

$1.50

Price Target Upside581.82% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Genetic Testing AdvancementsThe genomics test can accurately identify SNPs in the HTR3A, HTR3B, and SLC6A4 gene, as well as long and short forms of the SLC6A4 promoter.

Regulatory ProgressWith FDA alignment secured following the positive End-of-P2 meeting in September, Adial is now advancing preparations for its registrational P3 study.

Strategic PartnershipsAdial announced a collaboration agreement with Genomind following successful analytical validation of a cheek swab collection method for testing patients both in clinical and commercial applications.

Bears Say

Adial Pharmaceuticals News

Adial announces publication of international patent application for AD04

Adial Pharmaceuticals (ADIL) announced the publication of the international patent application for AD04, filed in July 2024. AD04...

20d ago

ADIL

Adial Pharmaceuticals announces immediate resignation of board director

Adial Pharmaceuticals ( ($ADIL) ) has issued an update. On January 5, 2025, Adial Pharmaceuticals announced that James...

27d ago

ADIL

Adial Pharmaceuticals Secures $2.86M Through Warrant Agreement

Adial Pharmaceuticals ( ($ADIL) ) just unveiled an update. On November 25, 2025, Adial Pharmaceuticals entered into a...

2M ago

ADIL

Adial Pharmaceuticals announces $2.86M warrant inducement transaction

Adial Pharmaceuticals (ADIL) announced its entry into a warrant inducement agreement with an existing healthcare-focused institutional investor of...

2M ago

ADIL

Strategic Advancements and Collaborations Propel Adial Pharmaceuticals’ Buy Rating

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Adial Pharmaceuticals. The associated price target...

3M ago

ADIL

Is ADIL a Buy, Before Earnings?

Adial Pharma (ADIL) is scheduled to report 3rd quarter earnings on 11/18/2025. Regarding Q3 estimates, Wall Street analysts...

3M ago

ADIL

Adial Pharmaceuticals reports Q3 net loss $1.8M vs $2.2M last year

Cash and cash equivalents were $4.6 million as of September 30, 2025, compared to $5.9 million as of...

3M ago

ADIL

Strategic Advancements and Genetic Testing Propel Adial Pharmaceuticals to a Buy Rating

Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Adial Pharmaceuticals and keeping the price target...

4M ago

ADIL

Adial Pharmaceuticals partners with Genomind for Precision Medicine Testing

Adial Pharmaceuticals (ADIL) announced the successful completion of the analytical validation of a cheek swab collection method for...

4M ago

ADIL

CoreWeave initiated, Instacart downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

4M ago

FCX

Adial Pharmaceuticals upgraded to Buy from Hold at Maxim

Maxim upgraded Adial Pharmaceuticals (ADIL) to Buy from Hold with a $1.50 price target Published first on TheFly...

4M ago

ADIL

Adial Pharmaceuticals Advances AD04 with FDA Support

Adial Pharmaceuticals ( ($ADIL) ) has shared an update. On September 16, 2025, Adial Pharmaceuticals announced receiving final...

5M ago

ADIL

Adial announces receipt of final meeting minuts from EOP2 meeting with FDA

Adial Pharmaceuticals (ADIL) announced receipt of the final meeting minutes from its End of Phase 2, EOP2, Meeting...

5M ago

ADIL

Adial Pharmaceuticals Granted Nasdaq Compliance Extension

An update from Adial Pharmaceuticals ( ($ADIL) ) is now available. On September 2, 2025, Adial Pharmaceuticals received...

5M ago

ADIL

ADIL FAQ

What was Adial Pharmaceuticals Inc’s price range in the past 12 months?

Adial Pharmaceuticals Inc lowest stock price was $0.21 and its highest was $1.30 in the past 12 months.

What is Adial Pharmaceuticals Inc’s market cap?

Adial Pharmaceuticals Inc’s market cap is $5.92M.

When is Adial Pharmaceuticals Inc’s upcoming earnings report date?

Adial Pharmaceuticals Inc’s upcoming earnings report date is Mar 26, 2026 which is in 51 days.

How were Adial Pharmaceuticals Inc’s earnings last quarter?

Adial Pharmaceuticals Inc released its earnings results on Nov 14, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.14 by $0.06.

Is Adial Pharmaceuticals Inc overvalued?

According to Wall Street analysts Adial Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Adial Pharmaceuticals Inc pay dividends?

Adial Pharmaceuticals Inc does not currently pay dividends.

What is Adial Pharmaceuticals Inc’s EPS estimate?

Adial Pharmaceuticals Inc’s EPS estimate is -0.08.

How many shares outstanding does Adial Pharmaceuticals Inc have?

Adial Pharmaceuticals Inc has 27,779,263 shares outstanding.

What happened to Adial Pharmaceuticals Inc’s price movement after its last earnings report?

Adial Pharmaceuticals Inc reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.14. Following the earnings report the stock price went up 1.881%.

Which hedge fund is a major shareholder of Adial Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in ADIL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Adial Pharmaceuticals Inc

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Adial Pharmaceuticals (ADIL) Earnings & Revenues

Historic Earnings Reports

ADIL Stock 12 Month Forecast

Average Price Target

$1.50

▲(581.82% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","-1":"-$1","-0.25":"-$0.25","0.5":"$0.5","1.25":"$1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.213,0.312,0.411,0.51,0.609,0.708,0.8069999999999999,0.9059999999999999,1.005,1.1039999999999999,1.2029999999999998,1.302,1.401,{"y":1.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.213,0.312,0.411,0.51,0.609,0.708,0.8069999999999999,0.9059999999999999,1.005,1.1039999999999999,1.2029999999999998,1.302,1.401,{"y":1.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.213,0.312,0.411,0.51,0.609,0.708,0.8069999999999999,0.9059999999999999,1.005,1.1039999999999999,1.2029999999999998,1.302,1.401,{"y":1.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.83,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.785,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.656,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.78,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.695,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.316,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.455,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.376,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.37,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.349,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.313,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.22,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.213,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >